Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) as a Treatment for Wet AMD

Stock Information for Outlook Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Outlook Therapeutics Inc.

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) Accepted by FDA

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.